# Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

> **NCT05002686** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Albumin-Paclitaxel
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiation
- **PROCEDURE:** Radical gastric cancer surgery

## Key facts

- **NCT ID:** NCT05002686
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-07
- **Primary completion:** 2023-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002686, "Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05002686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*